COMMUNIQUÉS West-GlobeNewswire

Rakovina Therapeutics Announces Extension of Non-Brokered Private Placement
12/03/2026
VANCOUVER, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV; FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through [...]
SK pharmteco annonce la certification CGMP de son site de production de vecteurs viraux à échelle commerciale en France
12/03/2026
RANCHO CORDOVA, Californie, 12 mars 2026 (GLOBE NEWSWIRE) -- SK pharmteco a annoncé aujourd'hui le succès de la certification CGMP de son usine de fabrication à Corbeil-Essonnes, en France. Cette usine de pointe est [...]
HealthEx Partners with Microsoft to Bring Consumers’ Personal Health History to Copilot Health
12/03/2026
Partnership combines digital identity, comprehensive health records, and consent infrastructure to power Microsoft’s new personalized, AI-powered health insights LAS VEGAS, March 12, 2026 (GLOBE NEWSWIRE) -- HIMSS [...]
Serotonin Centers Introduces New Medical Longevity Model for the Fitness Industry
12/03/2026
Turnkey partner platform brings medically supervised weight loss, hormone optimization and longevity services into gyms and health clubs nationwide ORLANDO, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Serotonin Centers [...]
Cloudcure Launches Companion App to Close Clinical Adherence Gap in Metabolic Health
12/03/2026
Toronto, ON, March 12, 2026 (GLOBE NEWSWIRE) -- Cloudcure, a specialized health platform dedicated to improving metabolic health through evidence-based, personalized medicine, has announced the launch of its new weight [...]
Amoéba receives its first order from Koppert and confirms its transformation into a commercial company
12/03/2026
Chassieu, March 12, 2026 (GLOBE NEWSWIRE) -- Amoéba receives its first order from Koppert and confirms its transformation into a commercial company Chassieu (France), 11 March 2026 – 6:00 pm - Amoéba (FR0011051598 - [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 11 mars 2026
12/03/2026
Nombre total de droits de vote et d’actions composant le capital social au 11 mars 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
Chemed Corporation to Present at the Oppenheimer 36th Annual Healthcare Conference
12/03/2026
CINCINNATI, March 12, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE:CHE) today announced that it will deliver a virtual presentation at the Oppenheimer 36th Annual Healthcare Conference on Thursday, March 19, 2026, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026
12/03/2026
Disclosure of Share Capital and Voting Rights Outstanding as of March 11, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
12/03/2026
Please see enclosed pdf. Attachment 12032026_trading_in_shares_ALS
PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters
12/03/2026
ST. LOUIS and HINTON, West Virginia, March 12, 2026 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, is pleased to [...]
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
12/03/2026
DALLAS, March 12, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
Daré Bioscience Participates in Virtual Investor “What This Means” Segment
12/03/2026
Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical study, and what the program could mean for women’s health Access the segment [...]
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated [...]
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
12/03/2026
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial [...]
BioLongevity Labs Publishes 2026 Research Peptide Vendor Report as Global Synthesis Market Hits $1.9 Billion
12/03/2026
The report evaluates top peptide suppliers against documentation depth, analytical standards, and third-party testing practices. Akron, OHIO, March 12, 2026 (GLOBE NEWSWIRE) -- BioLongevity Labs, a U.S. GMP-certified [...]
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
12/03/2026
New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc [...]
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
12/03/2026
SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
ORYZON Expands Patent Protection for Iadademstat with Grant Decision in Mexico Covering Combinations with PD-1/PD-L1 Inhibitors
12/03/2026
Key combination for the treatment of Small Cell Lung Cancer MADRID and CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical [...]

Pages